1. A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats
- Author
-
Annette Shepard-Barry, Karel Pacak, Inna Lomakin, James F. Powers, Sun Jin Moon, Troy F. Langford, Yingbin Ouyang, Arthur S. Tischler, Brent H. Cochran, Richard W. Tothill, Hadley D. Sikes, Kassi T. Stein, Xue Zhang, James D. Baleja, and Andrew D Pattison
- Subjects
0301 basic medicine ,Cancer Research ,SDHB ,Endocrinology, Diabetes and Metabolism ,Adrenal Gland Neoplasms ,Cell Culture Techniques ,macromolecular substances ,Biology ,Gene mutation ,medicine.disease_cause ,Germline ,Rats, Sprague-Dawley ,Pheochromocytoma ,Transcriptome ,paraganglioma ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,cluster 1 ,Paraganglioma ,Cell Line, Tumor ,medicine ,Metabolome ,Animals ,Humans ,succinate dehydrogenase B ,rat ,xenograft ,cell culture ,Mutation ,model ,business.industry ,hypoxia ,Research ,medicine.disease ,pheochromocytoma ,Rats ,Disease Models, Animal ,030104 developmental biology ,Oncology ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,metabolome ,Erratum ,business - Abstract
Tumors caused by loss-of-function mutations in genes encoding TCA cycle enzymes have been recently discovered and are now of great interest. Mutations in succinate dehydrogenase (SDH) subunits cause pheochromocytoma/paraganglioma (PCPG) and syndromically associated tumors, which differ phenotypically and clinically from more common SDH-intact tumors of the same types. Consequences of SDH deficiency include rewired metabolism, pseudohypoxic signaling and altered redox balance. PCPG with SDHB mutations are particularly aggressive, and development of treatments has been hampered by lack of valid experimental models. Attempts to develop mouse models have been unsuccessful. Using a new strategy, we developed a xenograft and cell line model of SDH-deficient pheochromocytoma from rats with a heterozygous germline Sdhb mutation. The genome, transcriptome and metabolome of this model, called RS0, closely resemble those of SDHB-mutated human PCPGs, making it the most valid model now available. Strategies employed to develop RS0 may be broadly applicable to other SDH-deficient tumors.
- Published
- 2020
- Full Text
- View/download PDF